Institutional Repository UDD

A tetrameric peptide derived from bovine lactoferricin as a potential therapeutic tool for oral squamous cell carcinoma: A preclinical model

Show simple item record

dc.contributor.author Solarte, Victor Alfonso
dc.contributor.author Conget, Paulette
dc.contributor.author Vernot, Jean-Paul
dc.contributor.author Rosas, Jaiver Eduardo
dc.contributor.author Rivera, Zuly Jenny
dc.contributor.author Garcia, Javier Eduardo
dc.contributor.author Arango-Rodríguez, Martha
dc.date.accessioned 2017-08-30T13:52:23Z
dc.date.available 2017-08-30T13:52:23Z
dc.date.issued 2017
dc.identifier.citation PLoS One. 2017 Mar 30;12(3):e0174707
dc.identifier.uri http://hdl.handle.net/11447/1623
dc.identifier.uri http://dx.doi.org/10.1371/journal.pone.0174707
dc.description.abstract Oral squamous cell carcinoma is the fifth most common epithelial cancer in the world, and its current clinical treatment has both low efficiency and poor selectivity. Cationic amphipathic peptides have been proposed as new drugs for the treatment of different types of cancer. The main goal of the present work was to determine the potential of LfcinB(20–25)4, a tetrameric peptide based on the core sequence RRWQWR of bovine lactoferricin LfcinB(20–25), for the treatment of OSCC. In brief, OSCC was induced in the buccal pouch of hamsters by applying 7,12-Dimethylbenz(a)anthracene, and tumors were treated with one of the following peptides: LfcinB(20–25)4, LfcinB(20–25), or vehicle (control). Lesions were macroscopically evaluated every two days and both histological and serum IgG assessments were conducted after 5 weeks. The size of the tumors treated with LfcinB(20–25)4 and LfcinB(20–25) was smaller than that of the control group (46.16±4.41 and 33.92±2.74 mm3 versus 88.77±10.61 mm3, respectively). Also, LfcinB(20–25)4 caused acellularity in the parenchymal tumor compared with LfcinB(20–25) and vehicle treatments. Furthermore, our results demonstrated that both LfcinB(20–25)4 and LfcinB(20–25) induced higher degree of apoptosis relative to the untreated tumors (75–86% vs 8%, respectively). Moreover, although the lowest inflammatory response was achieved when LfcinB(20–25)4 was used, this peptide appeared to induce higher levels of IgG antibodies relative to the vehicle and LfcinB(20–25). In addition the cellular damage and selectivity of the LfcinB(20–25)4 peptide was evaluated in vitro. These assays showed that LfcinB(20–25)4 triggers a selective necrotic effect in the carcinoma cell line. Cumulatively, these data indicate that LfcinB(20–25)4 could be considered as a new therapeutic agent for the treatment of OSCC.
dc.format.extent 17
dc.language.iso en_US
dc.publisher PLoS
dc.subject cancer treatment
dc.subject hamsters
dc.subject apoptosis
dc.subject histology
dc.subject white blood cells
dc.subject cell membranes
dc.subject inflammation
dc.subject necrosis
dc.title A tetrameric peptide derived from bovine lactoferricin as a potential therapeutic tool for oral squamous cell carcinoma: A preclinical model
dc.type Artículo


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account